LLY241122C690000
- 58.77
- 0.000.00%
Eli Lilly and Co Newsroom
Wednesday Ends With Index Decline | Wall Street Today
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Eli Lilly's Flortaucipir Approved by UK Regulator to Test for Alzheimer's Disease
Express News | Mhra: Approves Flortaucipir (Tauvid) for Adults Showing Signs of Cognitive Impairment for Alzheimer’s Disease
Amgen's Obesity Candidate MariTide Must Mitigate Tolerability Issues to Compete With Blockbuster Tirzepatide, Truist Says
Erste Group Downgrades Eli Lilly and Co(LLY.US) to Hold Rating
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
Will weight loss drugs be included in the US medical insurance, becoming the strongest "roadblock" for the Trump team?
The "Dual Weight Loss Champions" led the significant rise.
Top Gap Ups and Downs on Tuesday: LLY, ZM, BBY and More
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
Eli Lilly and Co (LLY.US) cancels double injections, brewing super BD for muscle gain and fat loss.
GLP-1 dual heroes Semaglutide and Tirzepatide, the total sales in 2024 will exceed $40 billion, leading to a huge demand in the muscle-building drug market.
U.S. stocks closed: The Dow and S&P reached all-time highs, while general motors plunged nearly 9%.
① Most technology giants rose, only Tesla fell; ② Eli Lilly and Co rose by 4.5%, as Biden proposed health insurance coverage for weight loss drugs; ③ The Chinese concept stock Jinlong Index fell by 0.8%, Nio fell by 7.7%; ④ Apple proposed to increase investment by 0.1 billion US dollars to seek to lift the sales ban, but was rejected by the Indonesian government.
Eli Lilly and Co Options Spot-On: On November 26th, 120.59K Contracts Were Traded, With 340.93K Open Interest
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Novo and Lilly Surge as Amgen Stumbles in Competitive Weight-Loss Market
Amgen's weight loss drug has a remarkable 20% reduction effect, but with high side effects, causing the stock price to plummet by 12.3% at one point!
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
The Biden administration has proposed covering weight loss medications under Medicare, while Trump's team may become the biggest obstacle.
①The Biden administration has proposed expanding the coverage of federal medical care and medical subsidies to include weight loss drugs; ②The White House claims that these drugs can prevent type 2 diabetes, lower the risk of cardiovascular diseases such as heart disease, but currently they are too expensive for Americans. ③This proposal may be blocked by the Trump administration taking office next year, as Senator Kennedy opposes weight loss drugs.